Answers are grounded in this paper and cite their sources.
The optimal treatment strategy for malignant lymphoma in patients aged ≥90 years remains unclear. This single‑center retrospective study evaluated treatment patterns and outcomes in 14 patients aged ≥90 years diagnosed with lymphoma between January 2020 and April 2026. Clinical characteristics, treatments, adverse events, and overall survival (OS) were retrospectively analyzed. The median age was 92 years (range, 90‑95 years), and diffuse large B‑cell lymphoma was the most common subtype (57%). Initial treatments included chemotherapy (n=10), steroid monotherapy (n=3), and watchful waiting (n=1). All patients receiving combination chemotherapy required dose reductions to ≤70% of standard intensity. The curative‑intent chemotherapy group (n=8) had a median OS of 374 days, compared with 46 days in the palliative‑intent group (n=4; log‑rank P=0.00299). Grade ≥3 adverse events occurred in 90% of chemotherapy‑treated patients, with 50% developing infections. Curative‑intent chemotherapy was associated with longer survival in selected patients aged ≥90 years, although treatment‑selection bias precludes causal inference. Substantial toxicity persisted despite dose reductions, emphasizing the importance of individualized treatment decisions based on functional status, comorbidities, and patient preferences.
No takes yet. Share an insight, caveat, or question.
HARA et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: